News Search
|
All News Topics
>
Corporate Social Responsibility
;
Press Releases by Industry Channel
>
All Corporate Social Responsibility Press Releases
Kinexum Congratulates TIXiMED
Kinexum congratulates TIXiMED on obtaining clearance from the US FDA to commence clinical testing of its TIX100.
WASHINGTON, DC, UNITED STATES, July 23, 2024 /EINPresswire.com/ -- Kinexum congratulates TIXiMED (www.tiximed.com) on obtaining clearance from the US FDA to commence clinical testing of its TIX100, an innovative small molecule targeting TXNIP, for Type 1 and Type 2 Diabetes. This is a major milestone in the development of the company’s novel approach to the treatment of Type 1 and Type 2 diabetes and gives TIXiMED the go ahead to start its human clinical trials with TIX100.TIXiMED Receives IND Approval from the FDA for its Novel Oral Antidiabetic, TIX100.
Kinexum acted as regulatory advisor to TIXiMED in connection with its IND application.
For more information on Kinexum's services, please visit www.kinexum.com.
Michael Zemel
Kinexum Services
michaelzemel@kinexum.com
Powered by
Distribution channels:
Banking, Finance & Investment Industry, Business & Economy, Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry, Media, Advertising & PR
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
